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effects, which may not be evident in
short-term management. Switching from
second-line therapies to third-line
treatments and not to systemic corticos-
teroids may prove to be more eco-
nomic, decreasing health-care services
utilization.
In conclusion, our observations sug-
gests that the use of third-line therapies
should be augmented at the outset of
antihistamine treatment failure among
patients with CU in the community
setting. The use of safer and more
efﬁcient drugs after antihistamine treat-
ment failure is warranted in patients
with CU.
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TO THE EDITOR
Hyaluronan (HA), a major component of
the extracellular matrix, is a polysaccha-
ride of high molecular mass (105–107Da).
Half of HA in human body is found in
skin, mostly in dermis (Meyer and Stern,
1994). In epidermis, HA mainly localizes
to basal and spinous layers (Tuhkanen
et al., 1998), whereas a low amount of
smaller-size (o6×104Da) HA is found in
stratum corneum (Sakai et al., 2000). HA
has variously been reported to regulate
keratinocyte proliferation, differentiation,
and migration (Maytin et al., 2004; Passi
et al., 2004; Farwick et al., 2011). Yet, its
actual functions in epidermis remain
unclear. HA is synthesized at the plasma
membrane by three different synthases
called hyaluronan synthases 1–3 (HAS1,
HAS2, and HAS3). During spontaneous
differentiation of keratinocytes, HA of
high molecular mass accumulates simul-
taneously with increased HAS1 and
decreased HAS2/3 expressions (Malaisse
et al., 2014). Under physiological condi-
tions, HA catabolism is mainly because of
hyaluronidases (HYALs). Only three out
of the six HYAL genes in the human
genome encode an active enzyme: PH20
in the sperm, and HYAL1 and HYAL2 in
somatic tissues. In somatic tissues HYAL1
is by far the most active enzyme, whereasAccepted article preview online 27 July 2015; published online 20 August 2015
Abbreviations: HA, hyaluronan; HAS, hyaluronan synthase; HYAL, hyaluronidase; RHE, reconstructed
human epidermis; RT-qPCR, reverse transcription–quantitative PCR; TEER, transepithelial electric
resistance; WT, wild type
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the HYAL2 gene product displays a very
faint activity (Vigdorovich et al., 2005).
This study aimed at characterizing the
distribution and role of HYALs in
epidermis.
For studies with cultured cells,
normal abdominal keratinocytes were
obtained from abdominoplasties of
patients after written informed consent,
with the approval of the Medical Ethics
Committee of Clinic St Luc and in
accordance with the Declaration of
Helsinki Principles. Using human
keratinocyte monolayers we found
HYAL1 becomes more abundant and
active upon conﬂuence, concurrently
with epidermal differentiation (Supple-
mentary Figure S1 online). Although
HYAL2 mRNA is expressed in human
keratinocytes (Mattiuzzo et al., 2011;
Malaisse et al., 2014), the encoded
protein could not reliably be assessed
because of a lack of efﬁcient speciﬁc
antibodies. However, parallel increases
in HYAL1 protein abundance and
hyaluronidase activity suggests a minor
role, if any, for HYAL2.
We then turned to reconstructed
human epidermis (RHE), a more reliable
3D model to study epidermal morpho-
genesis in vitro. We found that HYAL1
expression and activity remain rela-
tively stable during RHE growth but
HYAL1 localization (immunoﬂuores-
cence) becomes progressively con-
densed in the granular layer (Figure
1a–e). Simultaneously, HA is increas-
ingly detected between keratinocytes of
basal and spinous layers (Malaisse et al.,
2014). Interestingly, HYAL1 and HA
never colocalize and HA cannot be
detected in granular and corniﬁed
layers because of HYAL1-dependent
HA degradation.
Histological sections of healthy
human skin conﬁrm HYAL1 signal is
prominent in the granular layer, whereas
HA mostly surrounds basal and spinous
keratinocytes (Figure 1e). HYAL1 cannot
be detected in oral mucosal epithelium
(Figure 1f) that lacks a granular layer
(Presland and Jurevic, 2002). HYAL1
activity is also clearly demonstrated
using zymographic analysis of human
epidermis extracts (Figure 1g). Together,
these results suggest speciﬁc overexpres-
sion of active HYAL1 enzyme once
keratinocytes become part of the
granular layer.
In macrophages and liver extracts, the
processed forms of HYAL1 are loca-
lized in lysosomes (Boonen et al., 2014;
Puissant et al., 2014). In accordance,
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Figure 1. Hyaluronidase-1 (HYAL1) abundance, activity, and distribution in monolayers of cultured human keratinocytes, in reconstructed human
epidermis (RHE) and in human epidermis. (a and b) Proteins were extracted every 48 hours, starting 2 days before conﬂuence (C− 2d) of keratinocyte
monolayers, until 4 days after conﬂuence (C+4d). (a) HYAL1 abundance detected using western blots. RPL13a was used as loading control and involucrin
(IVL) as a control of epidermal differentiation. (b) HYAL1 activity revealed using zymography. Brighter stripes correspond to HYAL1 enzymatic activities.
(c and d) Proteins were extracted from RHE on days 3, 5, 7, 9, and 11. Day 1 corresponds to exposure of RHE to air–liquid interface. (c) HYAL1 protein
detected by western blot analysis. RPL13a is used as loading control. (d) Brighter stripes correspond to enzymatic activities of HYAL1 detected by zymography.
(e) RHEs were processed for histology and ﬂuorescent detection of HA (green), HYAL1 (red), and nuclei (blue). Scale bar= 25 μm. (f) Human skin and oral
mucosa were ﬁxed, processed for histology, and stained for HYAL1 (red) and HA (green). Scale bars= 50 μm. (g) HYAL1 activity detected in total protein
extract from normal human epidermis using zymography.
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our data conﬁrm colocalization bet-
ween HYAL1 and lysosomal proteins
cathepsins B and D inside granular
keratinocytes (Supplementary Figure S2
online). This suggests that HA has to be
internalized in order to reach HYAL1 for
degradation.
To investigate the role of HYAL1
in HA processing in the skin, we
took advantage of HYAL1-deﬁcient
(Hyal1−/−) mice. These animals are
viable and fertile with no gross anoma-
lies (Martin et al., 2008). Skin histology,
epidermal stratiﬁcation, and distribution
of differentiation markers indeed appear
normal in Hyal1−/− mice (Figure 2a and
Supplementary Figure S3 online).
However, we found that large-size
(0.3− 3.0× 106 Da) HA accumulates in
their stratum corneum, in clear distinc-
tion to wild-type (WT) mice (Figure 2b
and c). Together, these data strongly
suggest that epidermal HYAL1 degrades
HA into smaller fragments during the
differentiation and migration pro-
cesses of keratinocytes through the
granular layer.
Enhanced impermeability of the epi-
dermis mainly relies on its hydrophobic
components (Bouwstra et al., 2000) as
well as on tight junctions. Nevertheless,
generation of hydrophilic HA fragments
in the upper layer of the epidermis is
believed to contribute to outside-in
hydration (Sakai et al., 2000).
However, we found that outside-in
permeability, superﬁcial pH, and trans-
epithelial electric resistance (TEER) are
unaffected in Hyal1− /− mice compared
with WT animals despite large differ-
ences in the size of superﬁcial epi-
dermal HA (Supplementary Figure S4
online). Other enzymes such as β-hex-
osaminidase could compensate for the
deﬁciency in HA degradation (Gushulak
et al., 2012), although the relative gene
expressions of HYAL2, HYAL3, and
subunits of β-hexosaminidases A and B,
measured using reverse transcription–
quantitative PCR (RT-qPCR), are similar
in WT and Hyal1−/− mice (Supple-
mentary Figure S5 online).
What is the importance of these new
observations? A classical model for HA
degradation was ﬁrst proposed in cul-
tures of rat keratinocyte monolayers
(Tammi et al., 2001). These authors
showed HA turnover involves endo-
cytosis of ∼ 25% of newly synthesized
HA, suggesting a balance between HA
synthesis and degradation is important
in epidermal keratinocyte homeostasis.
Our results in human and mouse
keratinocytes suggest the bulk of HA
degradation, which is dependent on the
presence of active HYAL1, takes place
mostly in the granular layer where
keratinocytes lose intra- and peri-
cellular HA as they are pushed upward
in the tissue. The high level of active
HYAL1 restricted to stratum granulosum
suggests this lysosomal enzyme is a
gate-keeper preventing high-molecular-
mass HA from slipping into the corneal
layer. HYAL1 thereby generates HA
fragments in stratum corneum. The role
of these fragments in the uppermost
layer of the skin remains to be explored.
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Figure 2. Skin histology, and hyaluronan (HA) concentration and size distribution in Hyal1−/− versus
wild-type (WT) mice. (a) Skin biopsies were processed for histology, stained using hemalun/erythrosine
(HE), or labeled for hyaluronidase-1 (HYAL1; green) and nuclei (blue). Bar=20 μm. (b) HA content in
stratum corneum of WT and Hyal1−/− mice was measured and normalized to weight of stratum corneum
(n= 10, mean± SEM, Mann–Whitney Test, ***Po0.001). (c) Each HA sample was compared on Sephacryl
S-1000 column with 2500, 500, and 150 kDa HA fragments. The amount of HA measured in each fraction
is represented by mean± SEM (n=10, two-way repeated measures analysis of variance (ANOVA),
*Po0.05, **Po0.01, ***Po0.001). Fractions containing maximal detection of reference fragments are
indicated (∇).
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SASH1 Is Involved in an Autosomal Dominant Lentiginous
Phenotype
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TO THE EDITOR
Skin pigmentation disorders are among
the most recognizable human diseases,
strongly impacting both health and qual-
ity of life. Lentigines are small, hyper-
pigmented skin macules, histologically
containing increased numbers of mela-
nocytes, typically producing elevated
amounts of melanin. Most lentigines
are caused by UV radiation and appear
with increasing age. However, lentigines
can also be inherited in an autosomal
dominant pattern; in these cases, lenti-
gines typically appear in childhood (see
review Bauer and Stratakis, 2005). We
previously reported autosomal dominant
inheritance of a unique lentiginous pig-
mentation disorder (Pacheco et al., 2002,
2004). Here, we report identiﬁcation of a
variant associated with this lentiginous
phenotype in the SASH1 gene, with
additional histological analysis of the
patients’ skin. All blood samples,
biopsies, photographs, and information
from subjects obtained after written
informed patient consent were approved
by the relevant institutional review boards
(including permission to publish images).
Our previous linkage analysis of this
family mapped the disease locus to a
10-Mb interval between 6q24.2-q25.2
(Pacheco et al., 2002, 2004). Linkage
analyses of two Chinese families also
mapped a similar pigmentation disorder
to the same region (Xing et al., 2003).
The overlapping linkage interval of
these three families is ﬂanked by
markers D6S1703 and D6S441.
In the current family, candidate genes
within the linkage interval were screened
for mutations, including all exons, 100 bp
of introns, and 2 kb of the ﬂanking
promoter region. DNA sequence analysis
of 17 affected and 18 unaffected family
members identiﬁed a heterozygous
missense substitution in SASH1, in exon
13, c.1556 G-4A, p. S519N (Figure 1a
and b). This variant was the only one that
co-segregated perfectly with disease,
and was not observed in 150 ethnically
matched normal controls, 20 melanoma
patients with lentigines, or in the UCSC
Genome, Ensembl, HapMap, NCBI
dbSNP, or the Japanese SNP variant
databases.
All affected family members exhibited a
similar phenotype of dark brown macules
of lentigines (Figure 1c and d), typically
presenting in the ﬁrst decade of life, most
prominent in sun-exposed areas. In some
cases, lentigines covered the face, trunk,
and extremities, and in other case,
occurred principally over the face and
distal extremities (Figure 1c and d).
The diagnosis of lentigines is based on
the presence of increased melanin pig-
mentation, higher density of melanocytes,
and characteristic elongation of rete ridges
—the inward projections of the epidermis
into the dermis (Figure 2a) (Montagna
et al., 1980). Tissue sections stained with
the melanocyte marker MART1 showed
an ~2-fold increase in melanocyte
number per mm of skin biopsy in both
the hyper-pigmented lesional and adja-
cent non-lesional skin of affected patients
(Figure 2). However, only lesional skin
has a dramatic increase in melanin
(Figure 2a). Sections stained with the
proliferation marker, Ki67, showed that
patients had ~2-fold more proliferating
cells in both lesional and non-lesionalAccepted article preview online 23 July 2015; published online 13 August 2015
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